Xtant Medical Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $40.82M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $23.00M | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $20.90M | $-0.02 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | Before market open | $32.40M | $0.00 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | $33.30M | $0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | $35.40M | $0.02 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | $32.90M | $0.00 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | During market hours | $31.50M | $-0.02 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $27.90M | $-0.04 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| full-year guidance | full-year | $99.00M to $103.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Xtant Medical filed with the SEC
Medical Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Reports First Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon’s HEMOBLAST® Bellows Product
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Completes Sale of its Coflex ® Assets and
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
Medical Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Medical Announces Definitive Agreements for the Sale of its Coflex ® and CoFix ® Spinal Implants and All
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue
Agreement terminated · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Xtant Medical Reports Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Medical Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
(Unaudited, in thousands, except share data)
Other events · EX-99.1 to Form 8-K
PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.2 to Form 8-K
Medical Announces $5.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Medical Reports Second Quarter 2024 Revenue Growth of 48%
Results of operations · EX-99.1 to Form 8-K
Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Xtant Medical Announces Record Full Year 2023 Revenue
Results of operations · EX-99.1 to Form 8-K
Medical Increases Revolving Credit Facility to $17 Million with MidCap Financial
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Record Third Quarter Revenue of $25 Million
Results of operations · EX-99.1 to Form 8-K
Medical Announces Acquisition of nanOss Production Operations from RTI Surgical
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Second Quarter Revenue Growth of 32%
Results of operations · EX-99.1 to Form 8-K
Medical Wins Auction for Surgalign’s Hardware and Biologics Business
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Announces $15 Million Private Placement
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Medical Appoints Lori Mitchell-Keller to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces First Quarter 2023 Revenue Growth of 38% and Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Medical Announces Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Acquires Coflex ® Product Line from Surgalign for $17 Million
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Appoints Mark Schallenberger as Chief Operations Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Announces Closing of Second Tranche of $9.75 Million Private Investment
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Closing of First Tranche of $9.75 Million Private Investment
Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Announces $9.75 Million Private Investment
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Medical Announces Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Announces First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Medical Announces Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K